• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science

    3/23/23 10:19:01 AM ET
    $CDTX
    $ELVN
    $IMPL
    $PEAR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CDTX alert in real time by email

    SAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. REZZAYO is the first new treatment option approved for patients with candidemia and invasive candidiasis in over a decade.

    REZZAYO was developed by Cidara Therapeutics, Inc. (NASDAQ:CDTX), a company seeded and then supported by 5AM Ventures through its Series A and Series B rounds. 5AM's Scott Rocklage served as chair of the board of directors from the company's inception in 2012 through 2019.

    "Success for 5AM Ventures is achieved when we make a difference in patients' lives," said Andrew Schwab, Managing Partner. "We are proud that REZZAYO can now be a life-saving alternative for patients confronted with difficult-to-treat and often deadly candidemia and invasive candidiasis."

    Kush Parmar, Managing Partner added "At 5AM Ventures, over the last 21 years, we have created and funded companies that have brought 20 life-changing products to market for patients with cardiovascular, respiratory and infectious diseases, as well as cancer, addiction and other neurological areas, and those requiring surgical intervention."

    5AM Ventures drives advances in breakthrough science through its investments across a wide spectrum of biotherapeutics and platform technologies and is currently investing out of its $450 million 5AM Ventures VII, L.P. and $300 million 5AM Opportunities II, L.P. funds.

    ABOUT 5AM VENTURES

    Founded in 2002, 5AM Ventures is a leading venture capital firm focused on building next-generation life science companies. Based in San Francisco and Boston, 5AM takes a hands-on approach to investing and company building, often going beyond traditional board roles to leverage our diverse team of scientists, clinicians, drug developers and executives throughout a company's life. With more than $2.2 billion raised since inception, 5AM has invested globally in 114 public and private companies.

    5AM has guided portfolio companies through 21 IPOs and 20 M&A exits. Since January 1, 2020, 5AM companies that exited into the public markets are CinCor Therapeutics (NASDAQ:CINC), Enliven Therapeutics (NASDAQ:ELVN), Entrada Therapeutics (NASDAQ:TRDA), Impel Therapeutics (NASDAQ:IMPL), Pear Therapeutics (NASDAQ:PEAR), RallyBio (NASDAQ:RLYB) and Vor Therapeutics (NASDAQ:VOR). Since January 1, 2020, 5AM companies that were acquired are Akouos, Inc. acquired by Eli Lilly for up to $610 million, Audentes Therapeutics (NASDAQ:BOLD) acquired by Astellas for $3 billion, CinCor Therapeutics (NASDAQ:CINC) acquired by AstraZeneca for up to $1.8 billion, Precision NanoSystems acquired by Danaher Corporation, and Purigen acquired by Bionano Genomics. For more information, please visit www.5amventures.com.

    CONTACT

    5AM Ventures

    Britt Inga Emerson, Investor Relations Manager

    Email: [email protected]



    Primary Logo

    Get the next $CDTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDTX
    $ELVN
    $IMPL
    $PEAR

    CompanyDatePrice TargetRatingAnalyst
    Vor Biopharma Inc.
    $VOR
    9/24/2025$55.00Hold → Buy
    Stifel
    Vor Biopharma Inc.
    $VOR
    6/30/2025$3.00Neutral → Buy
    H.C. Wainwright
    Cidara Therapeutics Inc.
    $CDTX
    6/18/2025$41.00Buy
    H.C. Wainwright
    Enliven Therapeutics Inc.
    $ELVN
    6/16/2025$37.00Buy
    Goldman
    Rallybio Corporation
    $RLYB
    4/9/2025Buy → Neutral
    H.C. Wainwright
    Cidara Therapeutics Inc.
    $CDTX
    3/12/2025$46.00Mkt Outperform
    Citizens JMP
    Cidara Therapeutics Inc.
    $CDTX
    1/27/2025Overweight
    Cantor Fitzgerald
    Enliven Therapeutics Inc.
    $ELVN
    12/13/2024$42.00Buy
    BTIG Research
    More analyst ratings

    $CDTX
    $ELVN
    $IMPL
    $PEAR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $30,045 worth of shares (1,500 units at $20.03) (SEC Form 4)

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    9/25/25 7:44:47 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND CEO Kintz Samuel sold $56,084 worth of shares (2,800 units at $20.03) (SEC Form 4)

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    9/25/25 7:42:57 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $135,697 worth of shares (7,000 units at $19.39) (SEC Form 4)

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    9/23/25 5:14:23 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDTX
    $ELVN
    $IMPL
    $PEAR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ra Capital Management, L.P. bought $99,999,988 worth of shares (2,272,727 units at $44.00) (SEC Form 4)

    4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

    6/30/25 4:56:56 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: Director Kim Peter S bought $731,682 worth of shares (50,000 units at $14.63), increasing direct ownership by 74% to 117,412 units (SEC Form 4)

    4/A - Entrada Therapeutics, Inc. (0001689375) (Issuer)

    6/18/25 4:32:46 PM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mineo Chrysa bought $73,896 worth of shares (3,320 units at $22.26) (SEC Form 4)

    4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

    6/4/25 4:23:24 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CDTX
    $ELVN
    $IMPL
    $PEAR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025

    BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from the Phase 3 study in China evaluating telitacicept in adults with primary Sjögren's disease, a study sponsored by Vor's collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), will be presented as a late-breaking poster presentation at ACR Convergence 2025, being held October 24-29, 2025, at McCormick Place in Chicago, Illinois. Late-Breaking Presentation Details Abstract Title: Efficacy and Safety of Telitacicept in Patients with Sjögren's Disease: Results from a Multicenter, Randomized,

    9/29/25 7:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations

    - Phase 3 study expected to enroll 6,000 participants starting in the Northern Hemisphere - Participants will include adults over 65 years of age in addition to individuals with high-risk co-morbidities and immune compromised status SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the first participants have been dosed in its Phase 3 trial to evaluate the safety and efficacy of CD388, a non-vaccine preventative of seasonal influenza, in populations at high-risk for complications of influenza. Based on feedback from

    9/25/25 4:01:00 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

    – Interim Data Support Advancing RLYB116 as a Differentiated Therapeutic and Enable Progression to Cohort 2 –    – Data Readouts for Completed Study Expected in 4Q 2025 – Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the completion of dosing of the first cohort in the Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study evaluating RLYB116, the Company's innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor. "We are encouraged by the data generated to date in this confirmatory multiple ascending dos

    9/25/25 8:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDTX
    $ELVN
    $IMPL
    $PEAR
    SEC Filings

    View All

    SEC Form 144 filed by Enliven Therapeutics Inc.

    144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

    9/29/25 5:19:09 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Vor Biopharma Inc.

    SCHEDULE 13G - Vor Biopharma Inc. (0001817229) (Subject)

    9/25/25 8:34:12 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Vor Biopharma Inc.

    S-8 - Vor Biopharma Inc. (0001817229) (Filer)

    9/24/25 4:59:12 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CDTX
    $ELVN
    $IMPL
    $PEAR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Vor Biopharma upgraded by Stifel with a new price target

    Stifel upgraded Vor Biopharma from Hold to Buy and set a new price target of $55.00

    9/24/25 7:54:22 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Biopharma upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Vor Biopharma from Neutral to Buy and set a new price target of $3.00

    6/30/25 7:56:45 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright resumed coverage on Cidara Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Cidara Therapeutics with a rating of Buy and set a new price target of $41.00

    6/18/25 7:57:17 AM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CDTX
    $ELVN
    $IMPL
    $PEAR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/13/21 2:21:35 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/7/21 1:04:43 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDTX
    $ELVN
    $IMPL
    $PEAR
    Leadership Updates

    Live Leadership Updates

    View All

    Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer

    CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer. Dr. Khan joins Vor Bio with over two decades of experience spanning medical affairs, commercial, and R&D functions. He has overseen more than 40 development programs in neurology, immunology, and infectious diseases, and successfully guided seven U.S. and global product launches in rare neurology and immunology indications. Most recently, Dr. Khan was Head of Neuromuscular Therapeutic Area, Medical Affairs at argenx, where h

    9/23/25 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

    CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Adi Osovsky, S.J.D. as General Counsel. Dr. Osovsky brings 17 years of corporate counsel and law firm experience in the biotechnology and pharmaceutical sectors. "We are delighted to welcome Adi to Vor Bio at this important stage in our growth," said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. "Adi's proven experience advising public biopharmaceutical companies on governance, compliance, and strategic transactions makes her an outstanding addition to our leadersh

    9/2/25 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Entrada Therapeutics Reports Second Quarter 2025 Financial Results

    -- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clinical trial sites in U.K. and EU activated for ELEVATE-44-201 and ELEVATE-45-201 -- -- Leadership team expanded with the additions of Navid Khan, PhD, as Senior Vice President of Medical Affairs and Kiran Patki, MD, MSc, FFPM, as Senior Vice President of Clinical Development -- -- Cash runway expected into Q2 2027 with $354 million in cash, cash equivalents and marketable securities as of June 30, 2025 -- BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) to

    8/6/25 7:00:00 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDTX
    $ELVN
    $IMPL
    $PEAR
    Financials

    Live finance-specific insights

    View All

    Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025

    SAN DIEGO, July 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its second quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, August 7, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Thursday, August 7, 2025Time:5:00 PM Eastern TimeUnited States:1-844-825-9789International:1-412-317-5180Conference

    7/24/25 8:00:00 AM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

    Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio's (NASDAQ:RLYB) full interest in their joint ENPP1 inhibitor program (REV102) and an associated backup molecule for the treatment of hypophosphatasia (HPP), a rare and debilitating genetic disorder. "We extend our sincere thanks to Rallybio for their invaluable partnership in advancing this program to its current stage," said David Hallett, Chief Scientific Officer of Recursion. "Having full ownership of this important program allows Recursion to accelerate the development of the first

    7/8/25 8:00:00 AM ET
    $RLYB
    $RXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza

    The study met its primary and all secondary efficacy endpoints for all dose groups Single doses of 450mg, 300mg and 150mg of CD388 conferred 76%, 61% and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo CD388 was well-tolerated with no safety signals observed End of Phase 2 meeting request has been submitted to the U.S. Food and Drug Administration (FDA) Cidara will host a conference call at 8:30 am ET on Monday, June 23rd, 2025 SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics,

    6/23/25 7:00:00 AM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CDTX
    $ELVN
    $IMPL
    $PEAR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/9/24 5:37:15 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/4/24 4:15:14 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/3/24 4:34:49 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care